# Integrated Biopharma Inc (INBP)

> Cited company facts from SEC filings, by Steadybase. Web page: https://steadybase.io/company/integrated-biopharma-inc/ JSON: https://steadybase.io/company/integrated-biopharma-inc.json Checked Nov 10, 2026. Latest filing read: Oct 28, 2026.

## Company

- Legal name: INTEGRATED BIOPHARMA INC
- Ticker: INBP (OTC)
- SEC CIK: 0001016504
- Industry: Pharmaceutical Preparations (SIC 2834)
- Headquarters: Hillside, NJ
- Fiscal year ends: June 30
- SEC filer category: Non-accelerated filer<br>Smaller reporting company
- Website: ibiopharma.com
- Investor relations: https://ir.ibiopharma.com/
- LinkedIn: https://www.linkedin.com/company/integrated-biopharma-inc
- Next earnings date: Nov 11, 2026 (estimated from past 8-K timing)

## Key facts

- Revenue: $43.9M for the fiscal year ended Jun 30, 2026 (10-K filed Sep 25, 2026). Source: https://www.sec.gov/Archives/edgar/data/1016504/000143774926031241/0001437749-26-031241-index.html
- Operating income: -$2.7M for the fiscal year ended Jun 30, 2026 (10-K filed Sep 25, 2026). Source: https://www.sec.gov/Archives/edgar/data/1016504/000143774926031241/0001437749-26-031241-index.html
- Net income: -$2.8M for the fiscal year ended Jun 30, 2026 (10-K filed Sep 25, 2026). Source: https://www.sec.gov/Archives/edgar/data/1016504/000143774926031241/0001437749-26-031241-index.html
- SG&A: $3.5M for the fiscal year ended Jun 30, 2026 (10-K filed Sep 25, 2026). Source: https://www.sec.gov/Archives/edgar/data/1016504/000143774926031241/0001437749-26-031241-index.html
- Employees: 134 as of Jun 30, 2026, as reported in an SEC filing. Source: https://www.sec.gov/Archives/edgar/data/1016504/000143774926031241/inbp20260630_10k.htm
- Shares outstanding: 31,059,610 as of Sep 23, 2026 (10-K filed Sep 25, 2026). Source: https://www.sec.gov/Archives/edgar/data/1016504/000143774926031241/0001437749-26-031241-index.html
- Auditor: Cbiz Cpas P.C., Morristown, New Jersey, named in the latest 10-K. Source: https://www.sec.gov/Archives/edgar/data/1016504/000143774926031241/inbp20260630_10k.htm

## Business

, a Delaware corporation (together with its subsidiaries, the “Company”), is engaged primarily in the business of manufacturing, distributing, marketing and sales of vitamins, nutritional supplements and herbal products. The Company’s customers are located primarily in the United States and Luxembourg.

Source: Item 1. Business, https://www.sec.gov/Archives/edgar/data/1016504/000143774926031241/inbp20260630_10k.htm

## Annual results

| Fiscal year ended | Revenue | Operating income | Net income | SG&A |
|---|---|---|---|---|
| Jun 30, 2026 | $43.9M | -$2.7M | -$2.8M | $3.5M |
| Jun 30, 2025 | $54.4M | $2.0M | $808,000 | $3.5M |
| Jun 30, 2024 | $50.3M | $251,000 | $112,000 | $3.6M |
| Jun 30, 2023 | $50.7M | $120,000 | -$34,000 | $3.9M |
| Jun 30, 2022 | $56.2M | $2.7M | $3.8M | $3.8M |

Each figure comes from the annual report for that year. Filing links for every figure: https://steadybase.io/company/integrated-biopharma-inc.json

## Officers and directors

- Christina Kay, Co-Chief Executive Officer. LinkedIn: https://www.linkedin.com/in/christina-kay-64988b. Source: Form 4 filed Dec 10, 2025, https://www.sec.gov/Archives/edgar/data/1016504/000106490125000002/0001064901-25-000002-index.htm
- Sheppard Riva, Co-Chief Executive Officer. Source: Form 4 filed Dec 10, 2025, https://www.sec.gov/Archives/edgar/data/1016504/000106490025000002/0001064900-25-000002-index.htm
- Dina Masi, Chief Financial Officer. LinkedIn: https://linkedin.com/in/dina-masi-7a923816. Source: Form 4 filed Dec 10, 2025, https://www.sec.gov/Archives/edgar/data/1016504/000134528125000011/0001345281-25-000011-index.htm

## Recent 8-K events

- Sep 25, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1016504/000143774926031247/inbp20260925_8k.htm
- Aug 20, 2026: Item 8.01, Other events. Source: https://www.sec.gov/Archives/edgar/data/1016504/000143774926028628/inbp20260820_8k.htm
- Jul 2, 2026: Item 1.01, Entry into a material definitive agreement; Item 1.02, Termination of a material definitive agreement; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1016504/000143774926022415/inbp20260630_8k.htm
- May 8, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1016504/000143774926015928/inbp20260507_8k.htm
- Apr 15, 2026: Item 8.01, Other events; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1016504/000143774926012368/inbp20260415_8k.htm
- Feb 18, 2026: Item 1.01, Entry into a material definitive agreement; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1016504/000143774926004553/inbp20260217_8k.htm
- Feb 11, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1016504/000143774926003808/inbp20260205_8k.htm
- Dec 1, 2025: Item 5.07, Submission of matters to a vote of security holders; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1016504/000143774925036573/inbp20251201_8k.htm
- Nov 10, 2025: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1016504/000143774925034091/inbp20251107_8k.htm
- Sep 23, 2025: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1016504/000143774925029717/inbp20250922_8k.htm

## Latest filings

- 8-K filed Sep 25, 2026: https://www.sec.gov/Archives/edgar/data/1016504/000143774926031247/inbp20260925_8k.htm
- 10-K filed Sep 25, 2026: https://www.sec.gov/Archives/edgar/data/1016504/000143774926031241/inbp20260630_10k.htm
- 10-Q filed May 8, 2026: https://www.sec.gov/Archives/edgar/data/1016504/000143774926015899/inbp20260331_10q.htm
- DEF 14A filed Oct 28, 2026: https://www.sec.gov/Archives/edgar/data/1016504/000143774926033764/inbp20261023_def14a.htm

## About this data

SEC EDGAR filings, read by Steadybase. Every value links to the filing it came from.
Steadybase covers US-headquartered public companies that file with the SEC. API and MCP access: https://steadybase.io/docs/